Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of trastuzumab deruxtecan in HER2-over-expressing or HER2-mutated unresectable/metastatic NSCLC
2017-004781-94Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab deruxtecan in non-small cell lung cancer (NSCLC) and adenosquamous lung carcinoma (ASCL) (2 cohorts), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Objective response rate (ORR). Started May 2018; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)adenosquamous lung carcinoma (ASCL)
Beyond the preview
Go deeper on 2017-004781-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004781-94.